KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xylem (XYL) Cash & Equivalents (2016 - 2025)

Xylem (XYL) has 16 years of Cash & Equivalents data on record, last reported at $1.5 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 31.94% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 31.94%, while the annual FY2025 figure was $1.5 billion, 31.94% up from the prior year.
  • Cash & Equivalents reached $1.5 billion in Q4 2025 per XYL's latest filing, up from $1.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.8 billion in Q2 2021 and bottomed at $705.0 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 128.42% in 2021, then plummeted 40.56% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $1.3 billion in 2021, then crashed by 30.02% to $944.0 million in 2022, then rose by 7.94% to $1.0 billion in 2023, then increased by 10.01% to $1.1 billion in 2024, then surged by 31.94% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.5 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.